Sales & Marketing News | pharmaphorum

News

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

News

ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.

News

Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.

News

Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.

News

ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.

News

Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.